Omalizumab is administered by which route:
Patients should be given a 3-4 month trial of therapy to show objective benefit. Omalizumab is usually given as a subcutaneous injection every 2-4 weeks and appears not to have significant side effects. Ref: Harrison's principle of internal medicine 17th edition, chapter 248.
Inhalation
Intravenous
Intranasal
Subcutaneous